Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Scilex Holding Company ( (SCLX) ) has provided an announcement.
On July 22, 2025, Scilex Holding Company entered into a Common Stock Purchase Agreement with Tumim Stone Capital, allowing Scilex to sell up to $100 million in common stock at its discretion, subject to certain conditions. Additionally, Scilex executed Warrant Exchange Agreements and an Option Agreement with Oramed Pharmaceuticals, involving the exchange and repurchase of warrants, which could impact the company’s financial strategy and shareholder value.
The most recent analyst rating on (SCLX) stock is a Buy with a $245.00 price target. To see the full list of analyst forecasts on Scilex Holding Company stock, see the SCLX Stock Forecast page.
More about Scilex Holding Company
Scilex Holding Company operates in the pharmaceutical industry, focusing on developing and commercializing non-opioid pain management products.
Average Trading Volume: 142,149
Technical Sentiment Signal: Sell
Current Market Cap: $61.45M
Learn more about SCLX stock on TipRanks’ Stock Analysis page.